Pharmacyclics, Inc. (PCYC)

[surf1944]

News Breaks March 27, 2012
08:42 EDT PCYC
theflyonthewall.com: Pharmacyclics target raised to $42 from $21 at Roth Capital
After Pharmacyclics disclosed information about its ibrutinib drug, Roth Capital thinks that the market potential for the lymphoma treatment is "quite large." The firm is impressed by the speed of the clinical program for the drug, and it maintains a Buy rating. :theflyonthewall.com